Mr. George Achilleos reports

NETRAMARK SELECTS FINN PARTNERS AS ITS PUBLIC RELATIONS AGENCY OF RECORD

Netramark Holdings Inc. has entered into an agreement with FINN Partners Inc., a global full-service marketing and communications agency with a strong presence in the life sciences sector, to provide public relations services in an effort to raise public awareness of the company, primarily in the United States.

"We have been looking for the right partner to help Netramark build its profile within both the pharmaceutical and financial communities. FINN Partners has the experience, reach and team to help us elevate the company's awareness amongst leaders that can provide a meaningful impact on our long-term goals," said George Achilleos, chief executive officer, Netramark.

"We are honoured to be selected by Netramark to maximize awareness of its revolutionary generative artificial intelligence and machine learning products focused on helping companies optimize their clinical trial outcomes," said David Carey, senior partner of FINN Partners.

FINN Partners brings significant experience providing public relations, investor relations and marketing services to help biotechnology and pharmaceutical companies navigate the complex health care communications environment. In addition, FINN Partners will draw on its deep experience supporting global clinical trials for numerous pharmaceutical companies, medical device manufacturers and research organizations to raise awareness of Netramark in both the pharmaceutical and financial industries.

FINN Partners does not have any interest, directly or indirectly, in Netramark or its securities, nor any right or intent to acquire such an interest.

About Netramark Holdings Inc.

Netramark is a leader in predictive clinical trial analytics through the development of artificial intelligence/machine learning solutions targeted within the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.